LIVE
BHVN
Biohaven Ltd. · Healthcare - Clinical-Stage Biopharmaceutical
$13.57
+61.74% this month
VERSUS
⟷
COMPARE
PTGX
Protagonist Therapeutics, Inc. · Healthcare - Clinical-Stage Biopharmaceutical
$112.86
+14.73% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BHVN
1
PTGX
3
Comparison scoreboard
PTGX LEADS 3/5AI Score
BHVN 26.7
PTGX ✓47.5
1Y Return
BHVN -5.70%
PTGX ✓+109.31%
Fwd P/E
BHVN -6.95
PTGX ✓-164.84
Target Up.
BHVN ✓+59.95%
PTGX +5.17%
Op. Margin
BHVN N/A
PTGX N/A
Metrics last refreshed: 6/20/2026
Quick take
BHVN vs PTGX Stock Comparison: AI Score, Valuation, Performance and Upside
BHVN (Biohaven Ltd.) and PTGX (Protagonist Therapeutics) are both clinical-stage biopharmaceutical companies with distinct therapeutic focus areas — Biohaven is exploring ion channel biology and neurological diseases with an early-stage pipeline, while Protagonist has a more advanced pipeline with a J&J partnership for rusfertide in polycythemia vera and gut-restricted IBD peptide technology. Both represent binary clinical trial risk investments in smaller biotech companies.
BHVN vs PTGX is CNS ion channel biology bet (Biohaven's early-stage neurological and psychiatric pipeline from Pfizer spinoff management team) versus partnered hematology/GI peptide development (Protagonist's rusfertide in polycythemia vera partnered with J&J plus gut-restricted IBD program) — neurological disease early pipeline versus more advanced rare disease and GI drug development with big pharma partnership validation.
Live analysis · updated 6/20/2026
PTGX holds the edge across 3 of 5 key metrics in this comparison. PTGX leads on both 1-year return (+109.31%) and forward P/E (-164.84x vs -6.95x for BHVN), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for BHVN (+59.95%) than for PTGX (+5.17%).
Normalized 1Y performance
BHVN
PTGX
Recent returns
BHVN
PTGX
Analyst price targets & sentiment
BHVN · 17 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.7/5.0)
Price target range
analyst low$9.00
analyst high$50.00
analyst mean$21.71
current price$13.57
+60.0% upside to analyst mean
PTGX · 13 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.4/5.0)
Price target range
analyst low$100.00
analyst high$137.00
analyst mean$118.69
current price$112.86
+5.2% upside to analyst mean
Who should consider this stock?
BHVN may suit investors who:
- →Want early-stage CNS drug development exposure with the Biohaven management team that successfully developed the first CGRP-blocking migraine therapy before the Pfizer acquisition
- →Value ion channel biology as a differentiated mechanistic approach to neurological and psychiatric diseases where existing treatments are inadequate
- →Accept the high-risk, early-stage pipeline profile of a clinical company with limited revenue requiring capital raises to advance programs through trials
PTGX may suit investors who:
- →Want clinical-stage biotech exposure with Johnson & Johnson partnership validation for rusfertide in polycythemia vera — J&J's participation provides financial support and de-risks the commercial execution
- →Value Protagonist's novel gut-restricted peptide platform as potentially enabling better-tolerated IBD therapies that avoid systemic immunosuppression side effects
- →Accept the binary risk of polycythemia vera pivotal trial results as the primary near-term catalyst determining the company's near-term value
Performance & AI score
| Metric | BHVN | PTGX |
|---|---|---|
| AI score | 26.7 | 47.5 |
| AI rank | #2566 | #607 |
| Latest close | $13.57 | $112.86 |
| 1M return | +61.74% | +14.73% |
| 6M return | +24.84% | +26.33% |
| 1Y return | -5.70% | +109.31% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BHVN | PTGX |
|---|---|---|
| 1Y ago | $9.43K (-5.7%) started 2025-06-18 | $20.93K (+109.3%) started 2025-06-18 |
| 5Y ago | $19.02K (+90.2%) started 2022-09-23 | $26.57K (+165.7%) started 2021-06-18 |
| 10Y ago | $19.02K (+90.2%) started 2022-09-23 | $96.46K (+864.6%) started 2016-08-11 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BHVN | PTGX |
|---|---|---|
| Market cap | $2.04B | $7.26B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -6.95 | -164.84 |
| Price/Sales | N/A | 98.00 |
| EV/Revenue | N/A | 88.81 |
| Analyst target | $21.71 | $118.69 |
| Target upside | +59.95% | +5.17% |
Growth, profitability & risk
| Metric | BHVN | PTGX |
|---|---|---|
| Revenue growth | N/A | 99.00% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | N/A | -104.86% |
| Operating margin | N/A | N/A |
| Profit margin | 0.00% | -154.88% |
| ROIC proxy | -333.00% | -17.06% |
| Return on equity | -333.00% | -17.06% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 3.31 | 1.83 |
| Debt/equity | 220.99 | 1.49 |
| Current ratio | 7.41 | 17.76 |
| Quick ratio | 6.68 | 17.51 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BHVN max drawdown56.99%
PTGX max drawdown16.38%
BHVN max wkly drop53.95%
PTGX max wkly drop10.92%
5Y risk snapshot
BHVN max drawdown86.96%
PTGX max drawdown85.79%
BHVN max wkly drop53.95%
PTGX max wkly drop71.47%
10Y risk snapshot
BHVN max drawdown86.96%
PTGX max drawdown85.79%
BHVN max wkly drop53.95%
PTGX max wkly drop71.47%
Performance metrics by period
| Period | Metric | BHVN | PTGX |
|---|---|---|---|
| 1Y | Growth | -5.70% | +109.31% |
| CAGR | -5.70% | +109.42% | |
| Sharpe ratio | 0.37 | 1.61 | |
| Max drawdown | 56.99% | 16.38% | |
| Max daily drop | 40.22% | 9.16% | |
| Max wkly drop | 53.95% | 10.92% | |
| 5Y | Growth | +90.17% | +165.74% |
| CAGR | +18.78% | +21.59% | |
| Sharpe ratio | 0.57 | 0.60 | |
| Max drawdown | 86.96% | 85.79% | |
| Max daily drop | 40.22% | 62.00% | |
| Max wkly drop | 53.95% | 71.47% | |
| 10Y | Growth | +90.17% | +864.62% |
| CAGR | +18.78% | +25.87% | |
| Sharpe ratio | 0.57 | 0.65 | |
| Max drawdown | 86.96% | 85.79% | |
| Max daily drop | 40.22% | 62.00% | |
| Max wkly drop | 53.95% | 71.47% |
Business comparison
| Category | BHVN | PTGX |
|---|---|---|
| Company | Biohaven Ltd. | Protagonist Therapeutics, Inc. |
| Sector | Healthcare - Clinical-Stage Biopharmaceutical | Healthcare - Clinical-Stage Biopharmaceutical |
| Industry | N/A | N/A |
| Core business | Biohaven Ltd. is the spinoff company created when Pfizer acquired Biohaven Pharmaceutical in 2022 — retaining the pipeline assets not included in the Pfizer acquisition (primarily CGRP migraine therapy pipeline, ion channel biology programs, and other CNS assets). Biohaven is pursuing neurological and psychiatric disease treatments with novel mechanisms including Kv7 ion channel modulators and myeloperoxidase inhibitors. | Protagonist Therapeutics is a peptide-based drug developer focused on GI (gastrointestinal) diseases and hematology — creating novel peptide drugs that mimic natural hormones and peptides to treat inflammatory bowel disease (IBD), polycythemia vera, and other hematological conditions. Protagonist's lead programs include rusfertide (for polycythemia vera) partnered with Johnson & Johnson. |
| Investor focus | Investors track Biohaven's clinical pipeline progress (particularly Kv7 channel modulators in epilepsy and psychiatric disorders), cash runway, partnering opportunities, and management's ability to advance multiple early-stage programs with limited resources as a spinoff company. | Investors track Protagonist's rusfertide regulatory progress (polycythemia vera partnership with J&J), the IBD pipeline (PN-943, gut-restricted inflammatory peptide), JNJ partnership milestones, clinical trial results for late-stage programs, and cash position relative to development timelines. |
BHVN strengths
- →Ion channel biology expertise — Biohaven's scientific foundation in ion channel targets (Kv7 channels, TRP channels) represents a mechanistic approach that may produce differentiated therapies for neurological conditions where current options are limited
- →Multiple early-stage pipeline assets create diversified risk — Biohaven is pursuing several programs simultaneously, reducing dependency on any single trial outcome
- →Management team's track record — the Biohaven team successfully developed rimegepant (Nurtec ODT), approved for migraine, before the Pfizer acquisition; this track record in CNS drug development is a positive signal for the new pipeline
PTGX strengths
- →Late-stage partnership with Johnson & Johnson — Protagonist's rusfertide program for polycythemia vera (a rare blood disorder) is partnered with J&J, providing upfront payments, development cost sharing, and significant milestone payments if approved
- →Rusfertide differentiation in polycythemia vera — rusfertide (a hepcidin mimetic) addresses polycythemia vera with a novel mechanism, potentially offering an alternative to phlebotomy and cytoreductive therapy for patients with inadequate control
- →Gut-restricted peptide technology — Protagonist's platform creates peptides that act locally in the GI tract without systemic absorption, potentially enabling IBD therapies with better safety profiles than systemic biologics
Risks to watch — BHVN
- →Early-stage pipeline risk — Biohaven's current programs are in early clinical development, requiring years of trials before potential approval; failure rates in early clinical programs are high
- →Limited revenue — as a clinical-stage company, Biohaven depends on partnership payments, milestone receipts, or capital raises rather than product revenue to fund operations
- →Cash position management — without product revenue, Biohaven's runway determines how far its pipeline can advance before needing additional capital
Risks to watch — PTGX
- →Binary event risk from phase 3 readouts — rusfertide and IBD pipeline pivotal trial results represent high-stakes binary events that could significantly move the stock in either direction
- →Small rare disease market for polycythemia vera — PV affects approximately 100,000 U.S. patients; peak sales potential is limited relative to larger indication biotechs
- →Competition in IBD from approved biologics — vedolizumab (Entyvio), biologics (Humira), and JAK inhibitors are approved alternatives; demonstrating differentiation for gut-restricted peptide IBD therapies requires head-to-head advantages
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
More comparisons
Browse all 1,000 comparisons →